Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
Muc-1 α-gal epitope (HyperAcute®) NCT00569387 Active, not recruiting II Muc-1 α-gal epitope (HyperAcute®) NCT00614601 Active, not recruiting II Muc-1 α-gal epitope (HyperAcute®) NCT01072981 ...
Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment of patients with HER2-positive gastric or gastroesophageal junction ...
NEW YORK – Oncologists used Reveal Genomics' predictive assay, HER2DX, to alter neoadjuvant and adjuvant ... 57 percent had another anti-HER2 agent added to Genentech's Herceptin (trastuzumab), such ...
You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...
TORONTO, ON / ACCESS Newswire / March 11, 2025 / Magna Terra Minerals Inc. (the "Company" or "Magna Terra") (TSXV:MTT) today announces that it has filed an early warning report in respect of Gold ...
Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback